ARENA PHARMACEUTICALS INC (ARNA) Stock Price, Quote, News and Overview
NASDAQ:ARNA - Nasdaq - Common Stock
ARNA Quote, Performance and Key Statistics
99.99
+0.06 (+0.06%)
The current stock price of ARNA is 99.99 null. In the past month the price increased by 7.01%. In the past year, price increased by 29.74%.
ARNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARNA
Company Profile
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
Company Info
ARENA PHARMACEUTICALS INC
6154 Nancy Ridge Dr
San Diego CALIFORNIA 92121 US
CEO: Amit D. Munshi
Employees: 448
Company Website: http://www.arenapharm.com/
Phone: 18584537200.0
ARENA PHARMACEUTICALS INC / ARNA FAQ
What is the stock price of ARENA PHARMACEUTICALS INC today?
The current stock price of ARNA is 99.99 null. The price increased by 0.06% in the last trading session.
What is the ticker symbol for ARENA PHARMACEUTICALS INC stock?
The exchange symbol of ARENA PHARMACEUTICALS INC is ARNA and it is listed on the Nasdaq exchange.
On which exchange is ARNA stock listed?
ARNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARENA PHARMACEUTICALS INC stock?
19 analysts have analysed ARNA and the average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99. Check the ARENA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARENA PHARMACEUTICALS INC worth?
ARENA PHARMACEUTICALS INC (ARNA) has a market capitalization of 6.17B null. This makes ARNA a Mid Cap stock.
How many employees does ARENA PHARMACEUTICALS INC have?
ARENA PHARMACEUTICALS INC (ARNA) currently has 448 employees.
What are the support and resistance levels for ARENA PHARMACEUTICALS INC (ARNA) stock?
ARENA PHARMACEUTICALS INC (ARNA) has a support level at 95.88. Check the full technical report for a detailed analysis of ARNA support and resistance levels.
Is ARENA PHARMACEUTICALS INC (ARNA) expected to grow?
The Revenue of ARENA PHARMACEUTICALS INC (ARNA) is expected to grow by 4629.54% in the next year. Check the estimates tab for more information on the ARNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARENA PHARMACEUTICALS INC (ARNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARNA, evaluating the profitability, health, valuation and growth aspects
- ARENA PHARMACEUTICALS INC (ARNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARENA PHARMACEUTICALS INC (ARNA) Sales and EPS estimates to see what analysts future expectations are.
- ARENA PHARMACEUTICALS INC (ARNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARENA PHARMACEUTICALS INC (ARNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARENA PHARMACEUTICALS INC (ARNA) Stock Chart to make your own analysis
- ARENA PHARMACEUTICALS INC (ARNA) Latest news and press-releases to stay up to date.
Does ARENA PHARMACEUTICALS INC (ARNA) stock pay dividends?
ARNA does not pay a dividend.
When does ARENA PHARMACEUTICALS INC (ARNA) report earnings?
ARENA PHARMACEUTICALS INC (ARNA) will report earnings on 2022-05-03.
What is the Price/Earnings (PE) ratio of ARENA PHARMACEUTICALS INC (ARNA)?
ARENA PHARMACEUTICALS INC (ARNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.84).
ARNA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ARNA. When comparing the yearly performance of all stocks, ARNA is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
ARNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARNA. While ARNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARNA Financial Highlights
Over the last trailing twelve months ARNA reported a non-GAAP Earnings per Share(EPS) of -8.84. The EPS decreased by -19.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1141511.11% | ||
| ROA | -78.55% | ||
| ROE | N/A | ||
| Debt/Equity | 0.05 |
ARNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to ARNA. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 2.6% and a revenue growth 4629.54% for ARNA